Related Experiment Video
Updated: Jun 21, 2026
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Targeting the Warburg effect in hematological malignancies: from PET to therapy
Mala Shanmugam1, Samuel K McBrayer, Steven T Rosen
1Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA. mala@northwestern.edu
Purpose Of Review:
To highlight key studies providing rationale for and utility in targeting glycolysis for the treatment of hematological malignancies.
Recent Findings:
Several therapeutic strategies are capitalizing on the diagnostic utility of 18fluoro-deoxyglucose positron emission tomography that relies on increased glycolysis and glucose utilization in tumor cells. Although aerobic glycolysis was initially proposed by Warburg to be due to mitochondrial impairment, recent studies have shown a preferential switch to glycolysis in tumor cells with functional mitochondria. Increased glucose consumption can be advantageous for a tumor cell through stimulation of cellular biosynthetic, energetic, and pro-survival pathways. We now have a greater appreciation for the utilization of glucose in specific metabolic pathways that in some aspects can be complemented with other nutrients such as glutamine. Targeting glucose consumption for the treatment of hematological malignancies seems to be a promising field that will require characterization of tumor cell specific targets to inhibit glucose uptake and/or glycolysis. It is imperative to further our understanding of the tumor cell metabolome to target cellular bioenergetics in the treatment of cancer.
Summary:
Targeting the glycolytic pathway for the treatment of hematological malignancies has sufficient rationale given the utility of fluoro-deoxyglucose positron emission tomography in diagnostic imaging. Further research is required in developing tumor cell specific therapeutics.
Insights
Targeting cancer cell glycolysis shows promise for treating blood cancers. Diagnostic imaging highlights this pathway, but new tumor-specific therapies are needed to inhibit glucose metabolism.
Area of Science:
- Biochemistry
- Oncology
- Metabolic pathways
Background:
- Aerobic glycolysis, or the Warburg effect, is a hallmark of cancer cells, involving increased glucose utilization.
- Recent research indicates that tumor cells with functional mitochondria preferentially utilize glycolysis for growth and survival.
- Glucose metabolism fuels essential cellular processes, including biosynthesis, energy production, and pro-survival signaling.
Purpose of the Study:
- To review studies supporting the targeting of glycolysis for hematological malignancy treatment.
- To explore the diagnostic utility of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in relation to cancer cell glycolysis.
- To identify the need for novel therapeutics that specifically inhibit glucose uptake and glycolysis in cancer cells.
Main Methods:
- Review of key scientific literature on cancer metabolism and therapeutic strategies.
- Analysis of studies utilizing 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in hematological malignancies.
- Examination of metabolic pathways, including glucose and glutamine utilization in tumor cells.
Main Results:
- 18-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging demonstrates increased glycolysis and glucose uptake in tumor cells, supporting its diagnostic value.
- Cancer cells exhibit a metabolic shift towards glycolysis, even with intact mitochondria, to support proliferation.
- Understanding the tumor cell metabolome is crucial for developing targeted metabolic therapies.
Conclusions:
- Targeting the glycolytic pathway is a rational therapeutic strategy for hematological malignancies, supported by diagnostic imaging findings.
- Further research is essential to develop tumor-specific therapeutics that inhibit glucose metabolism.
- A deeper understanding of cancer cell bioenergetics is key to advancing cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...